| Ola Yinka, MD | |
|
6009 W Parker Rd # 149-261, Plano, TX 75093-8120 | |
| (214) 274-9314 | |
| Not Available |
| Full Name | Ola Yinka |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 32 Years |
| Location | 6009 W Parker Rd # 149-261, Plano, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134167711 | NPI | - | NPPES |
| 4625083-10 | Medicaid | MI | |
| BCBS | Other | TX | 8EH302 |
| 190871704 | Medicaid | TX | |
| P00146883 | Other | MI | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | L9987 (Texas) | Primary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | L9987 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Crescent Medical Center Lancaster | Lancaster, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Anesthesia Partners, Pllc | 3870879828 | 10 |
| Lighthouse Anesthesia Pllc. | 9335470574 | 7 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Garland Anesthesia Consultants, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710047840 PECOS PAC ID: 1052300100 Enrollment ID: O20040512000580 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Solar Health, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376724948 PECOS PAC ID: 3577625524 Enrollment ID: O20081229000479 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Painmd Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710142344 PECOS PAC ID: 2567529464 Enrollment ID: O20090320000042 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Olayinka Adepitan, Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043595283 PECOS PAC ID: 5496912511 Enrollment ID: O20120201000454 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Radius Anesthesia Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891157475 PECOS PAC ID: 8123327996 Enrollment ID: O20160428001617 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Texas Anesthesia Partners, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144673468 PECOS PAC ID: 3870879828 Enrollment ID: O20170406000406 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Zenith Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497282594 PECOS PAC ID: 9335418714 Enrollment ID: O20170628000019 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Imed Physician Network, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063809465 PECOS PAC ID: 6608103155 Enrollment ID: O20190807001189 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Lighthouse Anesthesia Pllc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528616042 PECOS PAC ID: 9335470574 Enrollment ID: O20200331001918 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Entity Name | Hill Regional Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679189856 PECOS PAC ID: 6002220464 Enrollment ID: O20210126000758 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ola Yinka, MD 6009 W Parker Rd # 149-261, Plano, TX 75093-8120 Ph: (214) 274-9314 | Ola Yinka, MD 6009 W Parker Rd # 149-261, Plano, TX 75093-8120 Ph: (214) 274-9314 |
News Archive
About 1 in 4,000 infants has a brain injury known as pre- or perinatal brain lesions, mainly as a result of stroke, with risk factors involving both mothers and babies. Children with early brain lesions that affect one side of the brain often take longer to reach early language milestones; these delays normalize for many but persist for some.
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.
A University of Sydney researcher has won a grant to study how exposure to drugs during adolescence affects the brain and behaviour.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 2 days ago
Dr. Monica Ata, MONICA ATA D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5944 West Parker Rd, Suite 400, Plano, TX 75093 Phone: 972-980-0500 | |
Dr. Paul S Dereska, D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 3308 Preston Rd, Ste. 350-283, Plano, TX 75093 Phone: 214-471-5975 | |
Dr. Sameer Ali Syed, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3151 W 15th St, Plano, TX 75075 Phone: 214-817-4225 Fax: 972-674-2788 | |
Tejas Vasant Ozarkar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5425 W. Spring Creek Parkway, Suite 100, Plano, TX 75024 Phone: 972-596-1059 Fax: 972-612-5410 | |
Dr. Matt Ted Gubert, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 400 Chisholm Pl Ste 406, Plano, TX 75075 Phone: 972-588-4541 Fax: 469-304-0139 | |
Dr. Brad Richard Davis, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 801 E Plano Pkwy, Suite 100, Plano, TX 75074 Phone: 972-422-5941 Fax: 972-881-4390 |